According to the NIH in a 2015 program announcement, "There is no greater healthcare need than slowing or preventing Alzheimer’s disease." Today, therapeutic approaches to the development of an Alzheimer’s disease therapeutic have focused on the “magic bullet” approach. In this approach a single molecule is developed to target a protein, often amyloid-beta, in an attempt inhibit the formation of plaques. Alion’s approach has been quite different from the inception of the project. Our efforts are directed towards modulation of pathways of protein-protein interactions in a concerted effort to exert many simultaneous therapeutic effects.